The US Biosimilars Patent Litigation Outlook For 2019
By Joshua Whitehill and Michael Cottler (January 18, 2019, 3:49 PM EST) -- In 2010, President Barack Obama signed the Biologics Price Competition and Innovation Act into law as part of the Affordable Care Act, establishing an abbreviated regulatory pathway for biosimilar approvals and a unique litigation framework for resolving biosimilar-related patent disputes. The first biosimilar in the U.S., Sandoz Inc.'s Zarxio (filgrastim-sndz), did not reach the market through this pathway until late 2015. Since then, each year has seen more U.S. Food and Drug Administration approvals than the year before. 2018 was no different, boasting a record seven biosimilar approvals, bringing the total number to 16....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.